C-C chemokine receptor type-4 transduction of T cells enhances interaction with dendritic cells, tumor infiltration and therapeutic efficacy of adoptive T cell transfer

Moritz Rapp, Simon Grassmann, Michael Chaloupka, Patrick Layritz, Stephan Kruger, Steffen Ormanns, Felicitas Rataj, Klaus-Peter Janssen, Stefan Endres, David Anz, and Sebastian Kobold

**ABSTRACT**

T cell infiltration at the tumor site has been identified as a major predictor for the efficacy of adoptive T cell therapy. The chemokine C-C motif ligand 22 (CCL22) is highly expressed by immune cells in murine and human pancreatic cancer. Expression of its corresponding receptor, C-C chemokine receptor type 4 (CCR4), is restricted to regulatory T cells (Treg). We show that transduction of cytotoxic T cells (CTL) with CCR4 enhances their emigration into a pancreatic cancer model. Further, we show that binding of CCR4 with CCL22 strengthens the binding of T cell LFA-1 to dendritic cell (DC) ICAM-1 and increases CTL activation. In vivo, in a model of subcutaneous pancreatic cancer, treatment of tumor-bearing mice with CCR4-transduced CTL led to the eradication of established tumors in 40% of the mice. In conclusion, CCR4 overexpression in CTL is a promising therapeutic strategy to enhance the efficacy of adoptive T cell transfer (ACT).

**Abbreviations:** ACT, adoptive T cell transfer; APC, antigen-presenting cell; CCL2, chemokine C-C motif ligand; CCR, C-C chemokine receptor; CTL, cytotoxic T lymphocytes; DC, dendritic cell; ELISA, Enzyme-Linked Immunosorbent Assay; GFP, green fluorescent protein; ICAM-1, intercellular adhesion molecule-1; IL-2, interleukin-2; IFNγ, interferon gamma; LFA-1, lymphocyte function-associated antigen-1; OVA, Ovalbumine; PBMC, peripheral blood mononuclear cells; Treg, regulatory T cell; Teff, effector T cell.

**Introduction**

ACT is a powerful approach for the treatment of different cancer types.1 ACT uses tumor-specific T cells either isolated from the patient’s own tumor or rendered tumor specific through transduction with a given T cell or chimeric antigen receptor.2,4 The transfer of tumor antigen-specific cytotoxic T lymphocytes (CTL) can induce complete disease remission in some patients with metastatic melanoma,5 Epstein-Barr virus-positive non-Hodgkin lymphoma,6 acute lymphatic leukemia,7 B cell lymphoma8 or nasopharyngeal carcinoma.9 However, the capacity of adoptively transferred T cells to invade the tumor and to induce an efficient antitumor immune response is limited. Thus, only a small subgroup of patients benefit from ACT in the long term.10

Infiltration of CTL or other immune cells into the tumor is mainly regulated by the local chemokine milieu. Several chemokines are known to attract immunosuppressive cell populations that shield tumor cells from the host’s immune response.11,12 Chemotherapy and irradiation of tumors can enhance the migration of T cells into tumors, among other by altering the chemokine profile of the tumor environment. The induction of apoptosis and necrosis in tumor cells by chemotherapy and irradiation generates an inflammatory reaction, which promotes the recruitment of T cells into the tumor.13-15 However, a limitation is the lack of specificity and the high toxicity of these therapies.16 To circumvent these obstacles and to enhance specificity, we aimed to genetically modify CTL ex vivo prior to ACT to improve their entry into the tumor.

Determinants of T cell infiltration into tumors include adhesion molecules that enable lymphocytes to attach to and pass the endothelial barrier of blood vessels,2,17,18 and chemokine gradients sensed by receptors expressed on CTLs to attract T cells chemotactically toward tumors.19 The endothelial integrin intercellular adhesion molecule 1 (ICAM-1) and its receptor lymphocyte function-associated antigen 1 (LFA-1) are...
mandatory for the process of extravasation.20 Moreover, the interaction of LFA-1 on T cells with ICAM-1 on antigen-presenting cells (APC), is a prerequisite for APC-mediated T cell activation.21 The affinity of integrin receptors can be regulated by activation of chemokine receptors. CCR7, for example activates LFA-1 through a process known as inside-out-signaling: Binding of CCR7 by its ligand CCL21 changes the conformation of LFA-1 and its affinity for ICAM-1 is strongly increased.22

The chemokine CCL22 is expressed in many tumors and mediates the recruitment of Treg into the tumor tissue.11,23 The corresponding chemokine receptor CCR4 is highly expressed by Treg, whereas CTL lack CCR4 expression.24 We hypothesized that a strategy increasing the migration of CTL into the tumor could improve the therapeutic efficacy of ACT. In this context, CCR4 may be a promising candidate to increase CTL tumor infiltration and potentially to enhance antitumor effects of CTL by increasing the LFA-1 affinity for ICAM-1.

In this study, we show that the transduction of CCR4 into CTL enhances the LFA-1-mediated binding to DCs and increases the activation of CTL. We demonstrate that adaptively transferred CTL overexpressing CCR4 accumulate in pancreatic cancer and induce increased antitumor immune responses. We also show CCL22 expression in patient pancreatic cancer specimens as evidence that T-cell transduction with CCR4 may warrant further investigations for the treatment of human pancreatic cancer.

Results

CCL22 is over-expressed in experimental tumors of pancreatic cancer cells

We aimed to identify chemokines with strong intratumoral expression and with no expression of their corresponding chemokine receptors on CTL to explore unique chemoattractant stimuli for these cells. We hypothesized that the ne novo expression of such chemokine receptors in CTL prior to adoptive transfer could increase the capability of these chemokines to attract CTL into the tumor and to improve the therapeutic efficacy of ACT. In order to identify appropriate chemokines, we screened established subcutaneously induced murine Panc02-OVA tumors for C-C chemokine expression by realtime PCR (Fig. 1A). The strongest expression was found for the chemokines CCL2, CCL6, CCL7 and CCL22 (Fig. 1A). The CCL22-specific receptor CCR4 is not expressed on CTL. In contrast, CCR4 is highly expressed on Tregs and guides these cells into the tumor tissue.11 Thus, the ne novo expression of CCR4 in CTL could be a promising approach to increase tumor-directed migration of CTL in ACT. To validate the potential of CCL22 to selectively attract CCR4-expressing cells into the tumor tissue, we quantified the expression of CCL22 on protein level in tumor and in other organs of Panc02-OVA tumor-bearing mice by ELISA. Expression of CCL22 was strongest in the tumor and peripheral lymph nodes (Fig. 1B), suggesting that CCR4-mediated migration of T cells would be preferentially directed to these sites. In these tumors, we could identify CD11c-positive immune cells as the main source of CCL22-production (Fig. S1). For the second ligand of CCR4, CCL17, only low concentrations were detected in the same tissues (Fig. S2). Normal murine pancreas did not express detectable levels of either chemokine. We next investigated the expression of CCR4 on T cells in tumor-bearing mice. Cell populations from tumor, peripheral lymph nodes, spleen, lung and blood of Panc02-OVA tumor-bearing mice were analyzed for CCR4 expression on non-T cells (CD3neg), CTL (CD3+CD8+), Teff (CD3+CD4+CD25neg) and Treg (CD3+CD4+CD25+) (Fig. 1C). In all analyzed compartments, CCR4 was preferentially expressed on Treg (Fig. 1C). These experiments identify the CCL22–CCR4 axis as a potential target to improve CTL migration into Panc02-OVA tumors.

CCR4-transduced CTL specifically migrate toward CCL22 and effectively kill tumor cells in vitro

To test the ability of CCR4 to promote CTL migration, we transduced OVA-specific T cells from OT-1 transgenic mice with CCR4-GFP or with a non-functional mutant of CCR4 (CCR4del-GFP) (Fig. S3). In the trans-well assay, CCR4-GFP but not CCR4del-GFP expression mediated specific and dose-dependent migration of the transduced T-cells toward CCL22 (Fig. 2A and 2B). Specificity of migration was confirmed by enrichment of GFP-expressing cells in CCR4-GFP but not CCR4del-GFP-transduced OT-1 T cells (Fig. 2B). Dose-dependent migration and GFP enrichment of CCR4-GFP cells was also observed toward CCL17 (Fig. S4). CCL22 neutralization by antibody completely abrogated migration (Fig. 2A and 2B). To exclude that the overexpression of CCR4 alters the effector function of T cells, migration toward and cytotoxicity against Panc02-OVA-CCL22dox cells, a tumor cell line with doxycycline (Dox)-inducible expression of CCL22 were analyzed. We could show that tumor cell-derived CCL22 strongly promoted CCR4-GFP but not CCR4del-GFP-transduced OT-1 T cell migration (Fig. 2C). By analyzing cytotoxicity of the migrated cells, we could further show that CCR4-GFP-transduced CTL efficiently lysed Panc02-OVA-CCL22dox tumor cells. CCL22-blockade abrogated both migration and subsequent tumor cell lysis (Fig. 2C). Thus, transduction of CTL with CCR4 strongly enhances migration toward CCL22-expressing cells and promotes tumor cell lysis.

CCR4 enhances ICAM-1-dependent T cell activation

Substantial amounts of CCL22 are produced by mature DC in vivo.25 The process of CTL priming against tumor antigen requires the interaction of DC with the corresponding T cells. To investigate whether CCR4 expression in CTL influences DC-CTL interactions and in consequence CTL activation, cocultures of both cell types were imaged in vitro and analyzed for T cell activation. CCR4- and CCR4del-transduced OT-1 T cells were mixed at a 1:1 ratio and were co-cultured with OVA-primed DC derived from either wild-type or CCL22-deficient mice. After 6 h DC-CTL clusters were analyzed by confocal microscopy for the ratio of CCR4 to CCR4del within the clusters (Fig. 3A, top panels) and CCL22 concentration in the coculture supernatant was measured by ELISA (Fig. S5). Interestingly, clusters with CCL22-expressing DC derived from wild-type mice contained almost twice as many CCR4-expressing
CTL as CCR4del-expressing CTL (Fig. 3A, lower left panel). In contrast, equal amounts of CCR4- and CCR4del-transduced CTL clustered around DC derived from CCL22-deficient mice. These findings indicate that DC-derived CCL22 induces CCR4-mediated cell contacts between DC and CTL. An important factor of DC-T cell aggregation is the interaction of LFA-1 on T cells with ICAM-1 on DC. As chemokines can affect LFA-1-ICAM-1 interaction, we aimed to test whether this ligand-receptor pair mediates the enhanced clustering of CCR4-expressing CTL. Indeed, blocking of ICAM-1 completely abrogated the preferential accumulation of CCR4-expressing CTL (Fig. 3A, lower left panel). In addition, ICAM-1 blockade resulted in a significant reduction of cluster size in all conditions, irrespective of CCL22 expression (Fig. 3A, lower right panel). To elucidate whether CCL22 binding to CCR4 on T cells indeed enhances T cell LFA-1 affinity for ICAM-1, we analyzed the binding of recombinant ICAM-1 to CCL22-stimulated T cells. Indeed, in the presence of CCL22, 2-fold more CCR4-transduced T cells bound recombinant ICAM-1 than in the absence of CCL22, whereas no ICAM-1 binding increase was observed on CCR4del-transduced (Fig. 3B) or on untransduced GFP-negative T cells (Fig. S6A). Binding of ICAM-1 to CCL22-stimulated CCR4-transduced T cells was LFA-1 specific, as preincubation with an LFA-1 blocking antibody, completely abrogated ICAM-1 binding (Fig. S6B). We next tested the adhesion of T cells to immobilized (plate-bound) ICAM-1. CCL22 pretreatment significantly increased the adhesion of CCR4-transduced CTL to ICAM-1, while the binding of CCR4del-transduced cells was not affected by CCL22 (Fig. 3C). These results suggest that CCL22-CCR4 interactions indeed increase ICAM-1 to LFA-1 binding and thus enhances DC-T cell interaction. To test the functional consequence of the strengthened interaction of CCR4-transduced T cells with DC, we analyzed the activation of CCR4-
and CCR4del-transduced CTL by DC. In the presence of CCL22, the recognition of OVA presented on DC by CCR4-transduced OT-1 CTL was markedly increased compared to CCR4del-transduced OT-1 CTL, as measured by IL-2 and IFN-γ release (Fig. 3D). Again, the addition of ICAM-1 blocking antibody abrogated the CCL22-induced increase of T cell activation (Fig. 3D). These results suggest that the binding of ICAM-1 to LFA-1 contributes to the CCL22-induced enhancement of CCR4-over CCR4del-transduced CTL-DC interaction.

**CCR4-transduced CTL enhance the efficacy of adoptive T cell transfer in a subcutaneous Panc02 murine tumor model**

To examine whether CCR4 expression can increase the therapeutic efficacy of ACT, we made use of the Panc02-OVA syngeneic tumor, which expresses CCL22 and is known to be widely resistant to ACT. We mixed CD45.1+ CCR4-GFP-transduced OT-1 T cells and CD90.1+ CCR4del-GFP-transduced OT-1 T cells at a 1:1 ratio and adoptively transferred these cells into Panc02-OVA tumor-bearing CD45.2+CD90.2+ mice. One week after transfer, the GFP distribution among all transferred marker cells was analyzed in the spleen, the peripheral lymph nodes and the tumors by flow cytometry. Remarkably, CCR4-transduced T cells specifically enriched over CCR4del-transduced T cells in the tumor tissue but not in the spleen or total peripheral lymph nodes (Fig. 4A). When we analyzed lymph node sites individually, we found a slight enrichment in the axillary ipsilateral but not in the ipsilateral or contralateral inguinal lymph nodes (Fig. S7). Next, we treated mice bearing established Panc02-OVA tumors twice, at days 6 and 12, with either GFP-, CCR4del- or CCR4-transduced OT-1 T cells (by i.v. injection). Treatment with CCR4-transduced T cells resulted in inhibition of tumor growth and cured four out of eight mice compared to one out of eight mice ($p < 0.05$) in the control groups treated with GFP- or CCR4del-transduced OT-1 T cells (Fig. 4B and C). Tumor-free mice remained cured for the duration of the observation period (up to 70 d) and were protected from re-challenge with a lethal dose of Panc02-OVA tumor cells (Fig. 4D), suggesting established immunity against the Panc02-OVA cells and long-term persistence of the transferred T cells. These results suggest that CCR4 expression increases the migration of adoptively transferred T cells preferentially into the tumor and thereby enhances their therapeutic efficacy.
CCL22 is expressed by human pancreatic cancer and human CCR4-transduced CTL migrate toward CCL22

To examine whether CCL22 may be a promising target for improving ACT against human malignancies, we analyzed CCL22 expression in human pancreatic adenocarcinoma, the entity recapitulated in the murine model we used so far. In immunohistochemistry, CCL22 was expressed in all of 15 analyzed pancreatic cancer samples. It was expressed in cells that corresponded in size, shape and localization to infiltrating leukocytes, but not to cancer cells (Fig. 5A). To test if the impact of CCR4-transduction in murine T cells would also translate into human T cells, we retrovirally transduced primary T cells obtained from human peripheral blood mononuclear cells with CCR4 and CCR4del.
(PBMC) with human CCR4-GFP or GFP alone (Fig. S8). CCR4-GFP but not GFP transduction increased migration of transduced primary T cells toward CCL22 (Fig. 5B, left panel). Among the migrated cells, GFP-positive cells preferentially migrated upon CCR4-GFP transduction, but not in the control condition, indicating a specific chemotactic effect mediated through CCR4 (Fig. 5B, right panel). In summary, we show here that CCR4 transduction induces specific migration of

Figure 4. Transfer of CCR4-transduced OT-1 Tcells induces regression of established tumors. (A) Panc02-OVA tumor-bearing CD45.2<sup>+</sup> CD90.2<sup>+</sup> mice (WT) were i.v. injected with CCR4-GFP-transduced CD45.1<sup>+</sup> and CCR4del-GFP-transduced CD90.1<sup>+</sup> OT-1 CTL. One week after injection the GFP distribution among all transferred marker cells was analyzed by flow cytometry. The amount of CCR4-transduced T cells was normalized to the amount of CCR4del-transduced T cells. (B, C) Mice bearing established subcutaneous Panc02-OVA tumors were i.v. injected 6 and 12 d after tumor induction with 2 × 10<sup>6</sup> OT-1 T cells transduced with GFP, CCR4 or CCR4del and tumor growth and survival was monitored every second day. (D) Tumor-free mice were re-challenged by subcutaneous injection of a lethal number (0.5 × 10<sup>6</sup>) of Panc02-OVA tumor cells. Data are presented as mean ± SEM of eight mice and censored at the time, the first mice had to be sacrificed due to the predefined endpoints of the study and are representative for two independent experiments. For re-challenge experiments, all cured mice were used. Significance of tumor growth was calculated by two-way ANOVA with Bonferroni post-test correction, differences in survival were analyzed by log-rank test and p value of cell enrichment by unpaired Student’s t-test. *p < 0.05; **p < 0.01; ***p < 0.001.
primary human T cells toward CCL22, a chemokine that is expressed in human pancreatic cancers. Thus, in analogy to our findings in the murine tumor model of pancreatic cancer cells, CCR4 transduction of human T cells may be capable to improve adoptive T cell therapy in patients with pancreatic cancer.

Discussion

In patients suffering from hematological malignancies, ACT is a powerful treatment modality to treat even refractory disease. However, a major limitation for the use of ACT in the treatment of solid tumors is the impaired access of immune cells to the tumor tissue, resulting in limited efficacy. Strategies to improve tissue infiltration by adoptively transferred T cells, especially in tumor entities such as pancreatic ductal adenocarcinoma which feature dense and extended stroma, are critical for ACT success. We could recently show that transduction of CTL with a marker antigen may enable bispecific antibodies to specifically engage these T cells to the tumor cell and enhance ACT efficacy. Similarly, we could demonstrate using a novel PD1-CD28-fusion receptor, that these T cells can be rendered resistance against PD-L1 driven immune suppression. In these studies, while we initially hypothesized an enhancement of T cell infiltration, we found few infiltrating T cells in the tumor. Furthermore, after initial response, the tumors relapsed, suggesting that a more extensive T cell infiltration is required for effective and persistent ACT effects. Treg, in contrast to CTL, can be found in large numbers in experimental and human tumors. The main mechanism for the attraction of immunosuppressive cells and the relative repulsion of CTL from the tumor is the chemokine profile present in the tumor micromilieu. In the preclinical tumor model studied here, we could identify the CCL22 - CCR4 axis as central for Treg tumor infiltration, as has been suggested previously for other diseases and models. We reasoned that we could target this axis therapeutically to enhance ACT efficacy. We demonstrate a strong therapeutic impact of T cell transduction with CCR4 in a syngeneic tumor model, accompanied by the accumulation of CCR4-transduced OT-1-T cells in the tumor. Neither CCL22 nor CCL17 are expressed by pancreatic cancer cells, as shown in the present study, but by the surrounding immune cells both in mice and humans. Our results extend previous findings where CCR4 has been used to redirect T cells to the tumor cells in xenograft models. The present approach is novel in the sense that previous strategies have used chemokine receptors to redirect T cells to the tumor cells directly while none have tried to attract T cells by employing a chemokine secreted by non-tumor cells in or around the tumor, such as CCL22 in our model. Attracting T cells to the tumor tissue, instead of directly to the tumor cell, may be beneficial, since we could show that CCL22 also strengthens the interaction with APC such as DC and boosts antigen recognition in an integrin ICAM-1-dependent manner.

The previous studies on chemokine receptor-enhanced recruitment of T cells to tumors have been performed in xenograft models in immunodeficient mice. In these models, counteracting effects of immunosuppressive cells, such as Treg, are excluded and the transplanted tumors are the only tissue that expresses human chemokines for attracting human CTL. In contract, the results of the present study demonstrate the efficiency of CCR4-transduced CTL for tumor treatment in immunocompetent mice.

It is known that the function of integrin receptors can be regulated by certain chemokines and their receptors. Engagement of CCL21 to CCR7 changes the conformation of LFA-1 and thereby increases the affinity of LFA-1 for ICAM-1. Since DC express large amounts of ICAM-1, the interactions of LFA-1 and ICAM-1 are part of the immunological synapse formed by T cells and DC. Our results show that CCR4 transduction not only increases the infiltration of adoptively transferred CTL into the tumor but also enhances the ICAM-1 - LFA-1-dependent interaction with antigen-presenting DC. This in turn is a crucial step for the activation of CTL. At this interface, CCR4-transduced T cells seem to outcompete CCR4del-transduced, potentially due to a limited amount of interaction sites for T cells per DC. Thus, in the absence of CCL22 from DC or CCR4 on T cell the cluster composition but not the cluster size is altered.

While our data confirmed previously reported expression of CCL22 in murine pancreatic cancer, little is known about the expression of CCL22 in human pancreatic cancer. To test if the CCL22 - CCR4 axis could, in principle, be targeted in human cancer, we analyzed tissue specimens from 15 pancreatic ductal adenocarcinoma patients by immunohistochemistry. In all tumor samples, CCL22 expressing cells were found. Interestingly, infiltrating immune cells, but not tumor cells, appeared to be responsible for intratumoral CCL22 expression, as has been suggested before in other tumor entities. We could recently identify CD14+ and CD68+ myeloid cells as the origin
of CCL22 secretion at the tumor site in breast-cancer patients. However, if our expression data from the Panc02-OVA-model holds for pancreatic cancer, there the secreting cells may be either CD11c+ myeloid cells. CCL22 is homeostatically expressed by DCs in lymph nodes and other lymphatic tissues. Thus, attracting antigen-specific T cells to tumor-distant sites may be important in the safety assessment of the strategy, especially if the antigen chosen is not tumor selective and may become activated outside of the tumor tissue. However, under homeostatic conditions, CCL22 is not relevant for entry of T cells in the lymph node under homeostatic conditions but is controlled through CCL19 and CCL21. As a consequence, we could not find an overall enrichment in lymph nodes but only in distinct anatomical location at the edge of the tumor site. Our data provide evidence that CCR4-transduced T cells potentially rather drain into tumor associated nodes which may reduce the risk of offsite T cell activation through unspecified redirection.

In summary, our results indicate that CCR4 transduction of CTL may be a promising new approach for the therapy of patients with a CCL22-expressing tumor microenvironment. Given that arming T cells with CCR4 can only affect T cell activation in an antigen-specific manner, we suggest that equipping T cells with such a navigation system may enhance T cell efficacy without impacting safety.

We suggest that an analysis of the chemokine expression profile of human cancers may help to identify entities amenable for a disease specific chemokine-based targeting strategy to enhance the efficacy of ACT.

Methods

Cell lines

The murine pancreatic cancer cell line Panc02 and its ovalbumin-transfected counterpart Panc02-OVA have been previously described. The CCL22-expressing Panc02-OVA-CCL22^dox^ and MC38-OVA-CCL22^dox^ tumor cell lines were generated by lentiviral transduction with a construct containing a Dox-inducible CCL22 expression cassette. The transduction protocol has been described in detail. The packaging cell line Plat-E was a kind gift of W. Uckert (Berlin, Germany) and HEK 293T cells were obtained from ATCC (Manassas, USA). T cell line Jurkat was purchased from Life technologies (USA). Plat-E was a kind gift of W. Uckert (Berlin, Germany) and HEK-293T cells were obtained from ATCC (Manassas, USA). T cell line Jurkat was purchased from Life technologies (USA). All cells were cultured in DMEM with 10% fetal bovine serum (FBS, Life Technologies), 1% penicillin and streptomycin (PS) and 1% L-glutamine (all from PAA, Germany). 1 µg/mL puromycin and 10 µg/mL blasticidin (both Sigma, Germany) were added to the Plat-E medium. Primary murine and human T cells were cultured in RPMI 1640 with 10% FBS, 1% PS, 1% L-glutamine, 1% sodium pyruvate, 1 mM HEPES and 50 µM β-mercaptoethanol (PAA, Germany and Sigma, Germany).

Animal experiments

C57BL/6 mice transgenic for a T cell receptor specific for ovalbumin (OT-1) were purchased from The Jackson Laboratory, USA (stock number 003831). OT-1 mice were crossed with CD45.1 congenic marker mice (obtained from The Jackson Laboratory, stock number 002014) or with CD90.1 congenic marker mice (a kind gift from R. Obst, Munich, Germany) to generate CD45.1-OT-1 and CD90.1-OT-1 mice, respectively. CCL22 knockout mice were obtained from KOMP, USA. For animal experiments, C57BL/6 mice were purchased from Janvier, France. Tumors were induced by subcutaneous injection of 2 × 10^6 tumor cells and mice were treated by i.v. injection of T cells as indicated. For re-challenge experiments, mice were injected subcutaneously with 0.5 × 10^6 tumor cells in the flank opposite to the initial tumor. All experiments were randomized and blinded. Tumor growth and condition of mice was monitored every other day. All animal experiments were approved by the local regulatory agency (Regierung von Oberbayern).

Generation of new fusion constructs

All constructs were generated by overlap extension PCR and recombinant expression cloning into the retroviral pMP71 vector, as follows: CCR4-GFP consists of murine CCR4 (Uniprot Entry P51680 amino acids 1–360) linked to GFP; the CCR4del-GFP consists of murine CCR4 amino acids 1–313 linked to GFP and the human CCR4-GFP consists of human CCR4 (Uniprot Entry P51679 amino acids 1–360) linked to GFP.

Murine T cell transduction

The retroviral vector pMP71 (kindly provided by C. Baum, Hannover) was used for transfection of the ectopic packaging cell line Plat-E. Transduction protocols have been described in detail. In brief, for primary murine T cell transduction Plat-E cells were transfected and the produced retrovirus was used to transduce T cells. T cells were stimulated first by addition of anti-CD3 antibody, anti-CD28 antibody (ebioscience, clones 145-2C11 and 37.51, respectively) and IL-2, and subsequently by addition of anti-CD3 beads, anti-CD28 beads (Life technologies) and human IL-15 (Peprotech, Germany).

Human T cell transduction

CCR4-GFP was cloned into the retroviral vector pMP71. pMP71-CCR4-GFP or pMP71-GFP was used for transduction of human T cells. Transduction protocol has been described in detail. In brief, for human T cell transduction, HEK-293T cells were double-transfected with the respective retroviral vector and the encoding plasmid pDNA3.1-MLVg-p and pALF10A1 (kindly provided by W. Uckert, Berlin, Germany). The produced retrovirus was used to transduce T cells. T cells were stimulated using anti-CD3 and anti-CD28 antibodies (clones HIT3a and CD28.2, ebioscience) and IL-2 (Peprotech).

Flow cytometry

Multi-color flow cytometry was performed using a BD FACS Canto II (BD bioscience, Germany). Single cell suspensions were obtained from spleen, lymph nodes, lung, blood and tumor and were stained with following antibodies: anti-CD3-APC (clone 145–2C11, Biolegend), anti-CD4-APC/Cy7 (clone GK1.5, Biolegend), anti-CD8-PerCP (clone 53–6.7, Biolegend), anti-CD25 (clone 3C7, Biolegend), anti-IFNγ-FITC (clone...
XMGL.2, Biolegend), anti-mouse CD45.1 (APC, Clone A20, eBioscience), anti-mouse CD90.1-PeCy7 (clone OX7, Biolegend), anti-FOXP3-Pacific Blue<sup>TM</sup> (clone MF-14, Biolegend) and anti-CCR4-PE/Cy7 (clone 2G12, Biolegend). For isolating tumor-infiltrating lymphocytes, tumors were mechanically disrupted, incubated with 1 mg/mL collagenase and 0.05 mg/mL DNase (both from Sigma Aldrich) and passed through a cell strainer. Single cell suspensions were layered on a gradient of 44% Percoll (Biochrome, Berlin, Germany) and 67% Percoll prior to centrifugation at 800 g for 30 min. Lymphocytes were obtained from the interphase, were washed with PBS and used for flow cytometry analysis.

**Migration and killing assays**

Cell migration was evaluated using transwell plates (Corning) as previously described. In brief, 1 × 10<sup>5</sup> CCR4-GFP- or CCR4del-GFP-transduced CTL or Jurkat cells were placed onto a 5 μm pore filter in the upper chamber of a transwell plate with the lower chamber containing different concentrations of CCL22 or CCL17 (both from Peprotech). For antagonizing migration through neutralization of CCL22 10 ng/mL, anti-CCL22 antibody (clone 158132, R&D) was added to the lower chamber. After 3 h incubation at 37°C the migrated cells in the lower chamber were analyzed by flow cytometry. For migration assays in combination with killing assays, 5 × 10<sup>5</sup> CCR4-GFP- or CCR4del-GFP-transduced OT-1 CTL were placed in the upper chamber of a transwell plate containing 1 × 10<sup>5</sup> Panc02-OVA-CCL2<sub>diox</sub> or MC38-OVA-CCL2<sub>diox</sub> tumor cells with Dox-inducible CCL22 expression in the lower chamber in the presence or absence of 2 μg/mL Dox (Sigma-Aldrich) and 10 ng/mL anti-CCL22 antibody. After 3 h incubation at 37°C the upper chamber was removed. The CTL-mediated lysis of tumor cells in the lower was measured by LDH release (Promega) after another 6 h incubation at 37°C. The percentage of cytotoxicity was normalized as follows: % lysis = (release of the target condition–spontaneous release of tumor and T cells) / (maximal release of tumor cells–spontaneous release of tumor and T cells). The concentration of CCL22 in the supernatant of the tumor cells was measured by ELISA (R&D Systems, Minneapolis, MN, USA).

**Cytokine assays of tissue lysates**

Tissue homogenates were resuspended in lysis buffer (BioRad Laboratories, Hercules, CA, USA) and were centrifuged. Total protein concentration was measured by Bradford assay (BioRad Laboratories). All samples were diluted to a protein concentration of 10 mg/mL and CCL17 and CCL22 concentrations were measured by ELISA (R&D Systems). The final cytokine concentration was calculated as pg cytokine per mg protein in the respective lysate.

**RNA isolation and quantitative real-time PCR analysis**

Total RNA was extracted from subcutaneous tumors using High Pure RNA Isolation Kit (Qiagen, Valencia, CA) according to the manufacturer’s instructions. 1 μg of RNA was converted to cDNA using the RevertAid First strand cDNA Synthesis Kit (Fermentas, St. Leon-Rot, Germany). Quantitative real-time PCR amplification was performed with the Light Cycler Taq-Man Master (Roche Diagnostics, Mannheim, Germany) on a LightCycler 2.0 instrument (Roche Diagnostics) together with the Universal Probe Library System (Roche Diagnostics). Relative gene expression is shown as a ratio of the expression level of the gene of interest to that of hypoxanthine phosphoribosyltransferase (HPRT) RNA. Quantitative real-time PCR primers were obtained from Metabion (Planegg, Germany; for primer sequences see Table S1).

**ICAM-1 adhesion and flow cytometry assay**

For ICAM-1 adhesion assays, 10<sup>7</sup> T cells transduced with CCR4 or CCR4del were labeled with 10 μg/mL Calcein (Life Technologies). Flat bottom 96-well plates were coated with 100 μg/mL ICAM-1 (R&D) for 1 h and blocked using 2% BSA for 30 min. After washing with PBS, T cells were plated in 200 μL PBS at a concentration of 2 × 10<sup>5</sup> cells per mL and incubated for 1 h at 37°C. After washing 3 times with 200 μL PBS, remaining cells were lysed using 200 μL of 10% Triton X-100 and centrifugation at 800 g for 5 min. 100 μL of the supernatants were transferred into new plates and fluorescence was measured using an ELISA reader. For ICAM-1 binding assays, 0.1 × 10<sup>5</sup> CCR4-GFP- or CCR4del-GFP-transduced T cells were incubated with 200 ng/mL CCL22 (Peprotech) in the presence or absence of 10 μg/mL anti-LFA-1 antibody (clone H155–78, Biolegend) in a total volume of 50 μL cell adhesion buffer (PBS containing 10% FCS, 1 mM MgCl<sub>2</sub> and 1 mM CaCl<sub>2</sub>). After adding 50 μL of recombinant mouse ICAM1/human Fc chimera (10 μg/mL, R&D) and incubating for 15 min at room temperature, cells were washed using cell adhesion buffer and fixed with 1% PFA at 4°C for 30 min. Subsequently, cells were stained for 30 min at 4°C using an APC linked anti-human Fc antibody (clone HP6017, Biolegend) and analyzed using flow cytometry.

**Confocal microscopy and cytokine secretion assay**

CCR4del- and CCR4-transduced OT-1 CTL were labeled with PKH-26 and PKH-67 (Sigma, Germany), respectively, according to the manufacturer’s instruction. PKH-labeled CCR4- and CCR4del-transduced CTL (5 × 10<sup>5</sup>) were cultured in the presence or absence of 5 μg/mL anti-ICAM-1 antibody (clone YNL7.4, BioXCell) with non-labeled splenic DC (5 × 10<sup>5</sup>) in 96-well non-tissue round bottom plates as described before. DC were isolated with CD11c-microbeads (Miltenyi Biotec, Germany) from splenic single cell suspensions of C57BL/6 or CCL22-deficient mice. After 6 h culture in the presence of 5 μg/mL CpG 1826 (Coley Pharmaceutical Group) and 1 μg/mL OVA<sub>257–264</sub> peptide (InvivoGen) cells were gently transferred to a glass-bottomed dish and used for confocal microscopy. The CCL22 concentration in the supernatants was analyzed by ELISA. For cytokine secretion assays 2 × 10<sup>5</sup> CCR4del- or CCR4-transduced OT-1 CTL were cultured in the presence or absence of 5 μg/mL anti-ICAM-1 antibody with splenic DC (5 × 10<sup>5</sup>). After 2, 4, 6, 8 and 10 h culture in the presence of 5 μg/mL CpG 1826, 1 μg/mL OVA<sub>257–264</sub> peptide and 50 ng/mL CCL22 (Peprotech) IL-2 and IFNγ levels were analyzed by ELISA (R&D Systems) in the culture supernatants.
**Patient samples and tissue microarray (TMA) construction**

Formalin-fixed, paraffin-embedded tumor tissue of 15 patients with confirmed pancreatic ductal adenocarcinoma was retrieved from the archives of the Institute of Pathology of the Ludwig-Maximilians Universität München. TMA consisting of two cores of histologically confirmed PDAC tumor tissue, each 1.5 mm diameter, was constructed using a semiautomatic tissue arrayer (Beecher Instruments). Clinicopathological patient data was retrieved from the original pathology reports. This retrospective analysis was carried out according to the recommendations of the local ethics committee of the Medical Faculty of the Ludwig-Maximilians-Universität München.

**CCL22 immunohistochemistry and microscopy**

Immunohistochemical staining was performed on 2 to 3 μm thick TMA sections after deparaffinization and rehydration using the rabbit anti-human CCL22 antibody (1:350; Peprotech) and an alkaline phosphatase-conjugated secondary antibody for detection, including appropriate positive and negative control tissues. In each tissue core, two peritumoral regions containing high amounts of CCL22+ cells were examined and the number of CCL22+ cells of two high power fields (HPF) was determined. The average number of CCL22+ cells in each case was finally calculated by division by four. Exemplary microscopical images were acquired at 400-fold magnification using a camera-equipped Zeiss Axioskop microscope (Zeiss) and Zeiss Axiovision imaging software.

**Statistical analysis**

All data are presented as mean ± SEM and the statistical significance of differences were determined by the two-tailed Student’s t-test. Differences in tumor size were analyzed using two-way ANOVA with Bonferroni posttest corrections. Differences in survival were analyzed by log-rank (Mantel-Cox) test. Statistical analyses were performed using GraphPad Prism 6 (GraphPad Software). P values < 0.05 were considered significant.

**Disclosure of potential conflicts of interest**

No potential conflicts of interest were disclosed.

**Acknowledgments**

SE and SK are member of the German Center for Lung Research. SG received a stipend from the German Cancer Aid. Parts of this work have been performed for the doctoral theses of SG and MC at the Ludwig-Maximilians-Universität München.

**Funding**

This work was supported by the international doctoral program “i-Target: Immunotargeting of cancer” funded by the Elite Network of Bavaria (to SK and SE), the Melanoma Research Alliance (grant number N269626 to SE and SK), the Wilhelm Sander Stiftung (grant number 2014_A204 to SK), the Marie-Słodowska Curie innovative training network “IMMUTRAIN: training network for the immunotherapy of cancer,” funded under the H2020 program of the European Union (to SE and SK) and by LMU Munich’s Institutional Strategy LMUexcel within the framework of the German Excellence Initiative (to SE and SK).

**References**

1. Rosenberg SA. Raising the bar: the curative potential of human cancer immunotherapy. Sci Transl Med 2012; 4:127ps8; PMID:22461638; http://dx.doi.org/10.1126/scitranslmed.3003634
2. Kalos M, June CH. Adoptive T cell transfer for cancer immunotherapy in the era of synthetic biology. Immunity 2013; 39:49-60; PMID:23890063; http://dx.doi.org/10.1016/j.immuni.2013.07.002
3. Morgan RA, Chinnasamy N, Abate-Daga D, Gros A, Robbins PF, Zheng Z, Dudley ME, Feldman SA, Yang JC, Sherry RM et al. Cancer regression and neurological toxicity following anti-CD8−enriched versus unselected tumor-infiltrating lymphocytes for adoptive cell therapy for patients with melanoma. J Clin Oncol: Off J Am Soc Clin Oncol 2013; 31:2152-9; PMID:23650429; http://dx.doi.org/10.1200/JCO.2012.46.6411
4. Dudley ME, Gross CA, Somerville RP, Hong Y, Schaub NP, Rosati SF, White DE, Nathan D, Restifo NP, Steinberg SM et al. Randomized selection design trial evaluating CD8−enriched versus unselected tumor-infiltrating lymphocytes for adoptive cell therapy in patients with melanoma. J Clin Oncol: Off J Am Soc Clin Oncol 2013; 31:2152-9; PMID:23650429; http://dx.doi.org/10.1200/JCO.2012.46.6411
5. Dudley ME, Wunderlich J, Nishimura MI, Yu D, Yang JC, Topalian SL, Schwarzentruber DJ, Hwu P, Marincola FM, Sherry R et al. Adoptive transfer of cloned melanoma-reactive T lymphocytes for the treatment of patients with metastatic melanoma. J Immunol 2001; 24:363-73; PMID:11565838; http://dx.doi.org/10.1007/s00237-00107000-0012
6. Bollard CM, Aguilar L, Straathof KC, Gahn B, Huls MH, Rousseau A, Sixbey J, Gresik MV, Carrum G, Hudson M et al. Cytotoxic T lymphocyte therapy for Epstein-Barr virus+ Hodgkin’s disease. J Exp Med 2004; 200:1623-33; PMID:15611290; http://dx.doi.org/10.1084/ jem.20040890
7. Maude SL, Frey N, Shaw PA, Aplenc R, Barrett DM, Bunin NJ, Chew A, Gonzalez VE, Zheng Z, Lacey SF et al. Chimeric antigen receptor T cells for sustained remissions in leukemia. N Engl J Med 2014; 371:1507-17; PMID:25317870; http://dx.doi.org/10.1056/ NEJMoai407222
8. Kochenderfer JN, Dudley ME, Kassim SH, Somerville RP, Carpenter RO, Stelet-Stevenson M, Yang JC, Phan QG, Hughes MS, Sherry RM et al. Chemotherapy-refractory diffuse large B-cell lymphoma and indolent B-cell malignancies can be effectively treated with autologous T cells expressing an anti-CD19 chimeric antigen receptor. J Clin Oncol. 2015 Feb 20; 33(6):540-9; PMID:25154820; http://dx.doi.org/10.1200/JCO.2014.62.2025
9. Straathof KC, Bollard CM, Popat U, Huls MH, Lopez T, Morriss MC, Gresik MV, Gee AP, Russell HV, Brenner MK et al. Treatment of nasopharyngeal carcinoma with Epstein-Barr virus—specific T lymphocytes. Blood 2005; 105:1898-904; PMID:15542583; http://dx.doi. org/10.1182/blood-2004-07-2975
10. Slaney CY, Kershaw MH, Darcy PK. Trafﬁcking of T cells into tumors. J Immunol. 2015 Feb 20; 33(6):540-9; PMID:25154820; http://dx.doi. org/10.1200/JCO.2014.65.2025
11. Curiel TJ, Coukos G, Zou L, Alvarez X, Cheng P, Mottram P, Evdemon-Hogan M, Conejo-Garcia JR, Zhang L, Burrow M et al. Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat Med 2004; 10:942-9; PMID:15322536; http://dx.doi.org/10.1038/nm1093
12. Schlecker E, Stojanovic A, Eisen C, Quack C, Falk CS, Umanovski Y, Cerwenka A. Tumor-infiltrating monocyctic myeloid-derived suppressor cells mediate CCR5-dependent recruitment of regulatory T cells favoring tumor growth. J Immunol 2012; 189:5602-11; PMID:23152559; http://dx.doi.org/10.4049/jimmunol.1201018
13. Ganss R, Ryschich E, Klar E, Arnold B, Hammerling GJ. Combination of T-cell therapy and trigger of inflammation induces remodeling of the vasculature and tumor eradication. Cancer Res 2002; 62:1462-70; PMID:11889821

14. Hong M, Puaux AL, Huang C, Loumagne L, Tow C, Mackay C, Kato M, Prevost-Blondel A, Avril MF, Nardin A et al. Chemotherapy induced-autocrine expression of chemokines in cutaneous melanoma, favoring T-cell infiltration and tumor control. Cancer Res 2011; 71:6997-7009; PMID:21948969; http://dx.doi.org/10.1158/0008-5472.CAN-11-1466

15. Matsumura S, Wang B, Kawashima N, Braunstein S, Badura M, Cameron TO, Babb JS, Schneider RJ, Formenti SC, Dustin ML et al. Radiation-induced CXCL16 release by breast cancer cells attracts effector T cells. J Immunol 2008; 181:3099-107; PMID:18713980; http://dx.doi.org/10.4049/jimmunol.181.5.3099

16. June CH. Adoptive T cell therapy for cancer in the clinic. J Clin Invest 2007; 117:1466-76; PMID:17549249; http://dx.doi.org/10.1172/JCI32446

17. Kunkel EJ, Campbell DJ, Butcher EC. Chemokines in lymphocyte trafficking and intestinal immunity. Microcirculation 2003; 10:313-23; PMID:12851648; http://dx.doi.org/10.1080/mic.10.3-4.313.323

18. Madri JA, Graesser D. Cell migration in the immune system: the evolving inter-related roles of adhesion molecules and proteinases. Dev Immun 2000; 7:103-16; PMID:11097205; http://dx.doi.org/10.1155/2000/79045

19. Franciszkiewicz K, Boissonnas A, Boutet M, Combiadere C, Mami-Chouaib F. Role of chemokines and chemokine receptors in shaping the effector phase of the antitumor immune response. Cancer Res 2012; 72:6325-32; PMID:23222302; http://dx.doi.org/10.1158/0008-5472.CAN-12-1027

20. Takechi T, Moecavius P, Deduchovas O, Denucova O, Castro-Santa E, Buchler MW, Schmidt J, Ryschich E. AlphaL beta2 integrin is indispensable for CD8+ T-cell recruitment in experimental pancreatic and hepatocellular cancer. Int J Cancer 2012; 130:2067-76; PMID:21647874; http://dx.doi.org/10.1002/ijc.26223

21. Evans R, Patrak I, Svensson L, De Filippo K, Jones K, McDowall A, Hogg N. Integrins in immunity. J Cell Sci 2009; 122:215-25; PMID:19118214; http://dx.doi.org/10.1242/jcs.019117

22. Kliche S, Worbs T, Wang X, Degen J, Patzak I, Meineke B, Togni M, Rapp M, Dusovec O, Deduchovas O, Salnikova O, Castro-Santa E, Buchler MW, Schmidt J, Ryschich E. AlphaL beta2 integrin is indispensable for CD8+ T-cell recruitment in experimental pancreatic and hepatocellular cancer. Int J Cancer 2012; 130:2067-76; PMID:21647874; http://dx.doi.org/10.1002/ijc.26223

23. Iellem A, Mariani M, Lang R, Recalde H, Panina-Bordignon P, Sinigaglia F, D’Ambrosio D. Unique chemotactic response profile and specific expression of chemokine receptors CCR4 and CCR8 by CD4(+) CD25(+) regulatory T cells. J Immunol 2008; 181:4853-62; PMID:21908423; http://dx.doi.org/10.1182/jimmunol.2011-01-329656

24. Di Stasi A, De Angelis B, Rooney CM, Zhang L, Mahendravada A, Foster AE, Heslop HE, Brenner MK, Dotti G, Savolbo B. T lymphocytes coexpressing CCR4 and a chimeric antigen receptor targeting CD30 have improved homing and antitumor activity in a Hodgkin tumor model. Blood 2009; 114:3692-402; PMID:19377047; http://dx.doi.org/10.1182/blood-2009-03-209650

25. Moon EK, Carpenito C, Sun J, Wang LC, Kapoor V, Predina J, Riley J, June CH, Alldalma SM. Expression of a functional CCR2 receptor enhances tumor localization and tumor eradication by retargeted human T cells expressing a mesothelin-specific chimeric antigen receptor. Clin Cancer Res 2011; 17:4719-30; PMID:21610416; http://dx.doi.org/10.1158/1078-0432.CCR-11-0351

26. Peng W, Ye Y, Rabinovich BA, Liu C, Lou Y, Zhang M, Whittington M, Yang Y, Overwijk WW, Lizée G et al. Transduction of tumor-specific T cells with CXCR2 chemokine receptor improves migration to tumor and antitumor immune responses. Clin Cancer Res 2010; 16:5458-68; PMID:20889916; http://dx.doi.org/10.1158/1078-0432.CCR-10-0712

27. Bolomini-Vittori M, Montresor A, Giagulli C, Staunton D, Rossi B, Martinello M, Constantin G, Laudanna C. Regulation of conformer-specific activation of the integrin LFA-1 by a chemokine-triggered Rho signaling module. Nat Immunol 2009; 10:185-94; PMID:19136961; http://dx.doi.org/10.1038/ni.1691

28. Grakoui A, Bromley SK, Sumen C, Davis MM, Shaw AS, Allen PM, Dustin ML. The immunological synapse: a molecular machine controlling T cell activation. Science 1999; 285:221-7; PMID:10398592; http://dx.doi.org/10.1126/science.285.5425.221

29. Kedl RM, Rees WA, Hildeman DA, Trottier S, Schaefer B, Mitchell T, Kappler J, Marrack P. T cells compete for access to antigen-bearing antigen-presenting cells. J Exp Med 2000; 192:1105-13; PMID:11034600; http://dx.doi.org/10.1084/jem.192.8.1105

30. Vernon PJ, Loux TJ, Schapiro NE, Kang R, Muthuswamy R, Kalinski P, Dransart E, Badoual C, Gey A, Ravel P, Marcheteau E et al. A fusion receptor on PD-1-mediated immunosuppression in adoptive T cell therapy. J Natl Cancer Inst 2011; 103(9):725-36; PMID:2105028; http://dx.doi.org/10.1093/jnci/djr146

31. Pere H, Monnier Y, Bayry J, Quintin-Colonna F, Merillon N, Dransart E, Badoual C, Gey A, Ravel P, Marcheteau E et al. A CCR4 antagonist combined with vaccines induces antigen-specific CD8+ T cells and tumor immunity against self antigens. Blood 2011; 118:4853-62; PMID:21908423; http://dx.doi.org/10.1182/jimmunol.2011-01-329656

32. Tsurikawa T, Yaguchi T, Ohmura G, Ohta S, Kobayashi A, Kawamura N, Fujita T, Nakano H, Shimada T, Takahashi T et al. Autocrine and paracrine loops between cancer cells and macrophages promote lymph node metastasis via CCR4/CCL22 in head and neck squamous cell carcinoma. Int J Cancer 2013; 132:2755-66; PMID:23180648; http://dx.doi.org/10.1002/ijc.27866

33. Anth JP, Rapp M, Eber S, Koeltz VH, Thaler R, Hauben S, Knott M, Nagel S, Golic M, Wiedemann GM et al. Suppression of intra-tumoral CCL22 by type I interferon inhibits migration of regulatory T cells and blocks cancer progression. Cancer Res 2015 Nov 1; 75(21):4483-93; PMID:26432403; http://dx.doi.org/10.1158/0008-5472.
42. Godiska R, Chantry D, Raport CJ, Sozzani S, Allavena P, Leviten D, Mantovani A, Gray PW. Human macrophage-derived chemokine (MDC), a novel chemoattractant for monocytes, monocyte-derived dendritic cells, and natural killer cells. J Exp Med 1997; 185:1595-604; PMID:9151897; http://dx.doi.org/10.1084/jem.185.9.1595

43. Arias MA, Pantoja AE, Jaramillo G, Paris SC, Shattock RJ, Garcia LF, Griffin GE. Chemokine receptor expression and modulation by Mycobacterium tuberculosis antigens on mononuclear cells from human lymphoid tissues. Immunology 2006; 118:171-84; PMID:16771852; http://dx.doi.org/10.1111/j.1365-2567.2006.02352.x

44. Luther SA, Bidgol A, Hargreaves DC, Schmidt A, Xu Y, Paniyadi J, Matloubian M, Cyster JG. Differing activities of homeostatic chemokines CCL19, CCL21, and CXCL12 in lymphocyte and dendritic cell recruitment and lymphoid neogenesis. J Immunol 2002; 169:424-33; PMID:12077273; http://dx.doi.org/10.4049/jimmunol.169.1.424

45. Jacobs C, Duewell P, Heckelsmiller K, Wei J, Bauernfeind F, Ellermeyer J, Kissner U, Bauer CA, Dauer M, Eigler A et al. An ISCOM vaccine combined with a TLR9 agonist breaks immune evasion mediated by regulatory T cells in an orthotopic model of pancreatic carcinoma. Int J Cancer 2011; 128:897-907; PMID:20473889; http://dx.doi.org/10.1002/ijc.25399

46. Bauernfeind F, Rieger A, Schildberg FA, Knolle PA, Schmid-Burgk JL, Hornung V. NLRP3 inflammasome activity is negatively controlled by miR-223. J Immunol 2012; 189:4175-81; PMID:22984082; http://dx.doi.org/10.4049/jimmunol.1201516

47. Schaniel C, Pardali E, Sallusto F, Speletas M, Ruedl C, Shimizu T, Seidl T, Andersson J, Melchers F, Rolink AG et al. Activated murine B lymphocytes and dendritic cells produce a novel CC chemokine which acts selectively on activated T cells. J Exp Med 1998; 188:451-63; PMID:9687523; http://dx.doi.org/10.1084/jem.188.3.451

48. Onishi Y, Fehervari Z, Yamaguchi T, Sakaguchi S. Foxp3+ natural regulatory T cells preferentially form aggregates on dendritic cells in vitro and actively inhibit their maturation. Proc Natl Acad Sci U S A 2008; 105:10113-8; PMID:18635688; http://dx.doi.org/10.1073/pnas.071106105